Novan Inc
F:6LUA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
Reginn hf
ICEX:REGINN
|
IS |
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
CN |
|
C
|
Consensus Cloud Solutions Inc
NASDAQ:CCSI
|
US |
|
C
|
CSC Steel Holdings Bhd
KLSE:CSCSTEL
|
MY |
|
Alembic Ltd
NSE:ALEMBICLTD
|
IN |
|
Artivion Inc
NYSE:AORT
|
US |
|
S
|
Sats ASA
OSE:SATS
|
NO |
|
E
|
Ecit AS
OSE:ECIT
|
NO |
|
Taiwan-Asia Semiconductor Corp
TWSE:2340
|
TW |
|
Itau Unibanco Holding SA
NYSE:ITUB
|
BR |
|
A
|
Aspo Oyj
OMXH:ASPO
|
FI |
|
M
|
MBB SE
XBER:MBB
|
DE |
|
Emerald Resources NL
ASX:EMR
|
AU |
|
Visual China Group Co Ltd
SZSE:000681
|
CN |
Novan Inc
Total Equity
Novan Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Novan Inc
F:6LUA
|
Total Equity
$4.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Equity
$81.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
1%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Equity
$18.5B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
3%
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Equity
$86.5B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Equity
$52.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
16%
|
CAGR 10-Years
2%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Equity
$26.5B
|
CAGR 3-Years
36%
|
CAGR 5-Years
36%
|
CAGR 10-Years
6%
|
|
Novan Inc
Glance View
Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company is headquartered in Durham, North Carolina and currently employs 29 full-time employees. The company went IPO on 2016-09-21. The firm is engaged in researching, developing and marketing products for skin diseases. The firm is focused on dermatology and anti-infective therapies. Its technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action to treat a range of diseases. The firm has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, which is a topical gel with anti-viral properties for the treatment of viral skin infections, with focus on molluscum contagiosum. The firm is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19, targeting the reduction of viral shedding and transmission.
See Also
What is Novan Inc's Total Equity?
Total Equity
4.6m
USD
Based on the financial report for Dec 31, 2022, Novan Inc's Total Equity amounts to 4.6m USD.
What is Novan Inc's Total Equity growth rate?
Total Equity CAGR 1Y
-75%
Over the last year, the Total Equity growth was -75%.
